EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
EyePoint Pharmaceuticals (NASDAQ: EYPT) has granted non-statutory stock options to two new employees as inducement awards outside its 2023 Long-Term Incentive Plan. The grants, approved by the Compensation Committee on February 14, 2025, include options to purchase up to 21,000 shares of common stock at an exercise price of $6.50 per share.
The options have a ten-year term and follow a four-year vesting schedule, with 25% vesting on the first anniversary and the remaining shares vesting in equal monthly installments over the following three years. Vesting is contingent upon continued employment with EyePoint Pharmaceuticals.
EyePoint Pharmaceuticals (NASDAQ: EYPT) ha concesso opzioni su azioni non statutarie a due nuovi dipendenti come premi di incentivazione al di fuori del suo Piano di Incentivazione a Lungo Termine 2023. Le concessioni, approvate dal Comitato per la Compensazione il 14 febbraio 2025, includono opzioni per acquistare fino a 21.000 azioni ordinarie a un prezzo di esercizio di 6,50 dollari per azione.
Le opzioni hanno una durata di dieci anni e seguono un programma di maturazione di quattro anni, con il 25% che matura al primo anniversario e le azioni rimanenti che maturano in rate mensili uguali nei successivi tre anni. La maturazione è subordinata al mantenimento dell'impiego con EyePoint Pharmaceuticals.
EyePoint Pharmaceuticals (NASDAQ: EYPT) ha otorgado opciones de acciones no estatutarias a dos nuevos empleados como premios de inducción fuera de su Plan de Incentivos a Largo Plazo 2023. Las concesiones, aprobadas por el Comité de Compensación el 14 de febrero de 2025, incluyen opciones para comprar hasta 21,000 acciones ordinarias a un precio de ejercicio de $6.50 por acción.
Las opciones tienen un plazo de diez años y siguen un calendario de adquisición de cuatro años, con el 25% de las acciones adquiriéndose en el primer aniversario y las acciones restantes adquiriéndose en cuotas mensuales iguales durante los tres años siguientes. La adquisición está sujeta a la continuación del empleo con EyePoint Pharmaceuticals.
EyePoint Pharmaceuticals (NASDAQ: EYPT)는 2023년 장기 인센티브 계획 외부에서 유인 보상으로 두 명의 신규 직원에게 비법적 주식 옵션을 부여했습니다. 2025년 2월 14일 보상위원회에서 승인된 이 부여는 주당 $6.50의 행사 가격으로 최대 21,000주의 보통주를 구매할 수 있는 옵션을 포함합니다.
이 옵션은 10년의 기간을 가지며 4년의 분할 일정에 따라 1주년 기념일에 25%가 분할되고 나머지 주식은 다음 3년에 걸쳐 매달 동일한 금액으로 분할됩니다. 분할은 EyePoint Pharmaceuticals와의 고용 지속 여부에 따라 결정됩니다.
EyePoint Pharmaceuticals (NASDAQ: EYPT) a accordé des options d'achat d'actions non statutaires à deux nouveaux employés en tant que récompenses d'incitation en dehors de son Plan d'Incitation à Long Terme 2023. Les attributions, approuvées par le Comité de Rémunération le 14 février 2025, incluent des options pour acheter jusqu'à 21 000 actions ordinaires à un prix d'exercice de 6,50 $ par action.
Les options ont une durée de dix ans et suivent un calendrier d'acquisition de quatre ans, avec 25 % qui s'acquièrent à la première date anniversaire et les actions restantes s'acquérant en versements mensuels égaux au cours des trois années suivantes. L'acquisition est subordonnée à la poursuite de l'emploi avec EyePoint Pharmaceuticals.
EyePoint Pharmaceuticals (NASDAQ: EYPT) hat zwei neuen Mitarbeitern außerhalb des langfristigen Anreizplans 2023 nicht-statutäre Aktienoptionen als Anreizpreise gewährt. Die Zuteilungen, die am 14. Februar 2025 vom Vergütungsausschuss genehmigt wurden, beinhalten Optionen zum Kauf von bis zu 21.000 Stammaktien zu einem Ausübungspreis von 6,50 $ pro Aktie.
Die Optionen haben eine Laufzeit von zehn Jahren und folgen einem vierjährigen Vesting-Plan, wobei 25% am ersten Jahrestag und die verbleibenden Aktien in gleichen monatlichen Raten über die nächsten drei Jahre fällig werden. Das Vesting ist abhängig von der Fortsetzung des Arbeitsverhältnisses mit EyePoint Pharmaceuticals.
- None.
- None.
WATERTOWN, Mass., Feb. 17, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).
The Company granted stock options to purchase up to an aggregate of 21,000 shares of EyePoint Pharmaceuticals common stock to two new employees. The stock options were granted on February 14, 2025. The grants were approved by the Compensation Committee and made as an inducement material to each employee entering into employment with EyePoint Pharmaceuticals in accordance with NASDAQ Listing Rule 5635(c)(4). The option awards have an exercise price of
About EyePoint Pharmaceuticals
EyePoint (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to help improve the lives of patients with serious retinal diseases. The Company's pipeline leverages its proprietary bioerodible Durasert E™ technology for sustained intraocular drug delivery. The Company’s lead product candidate, DURAVYU™ is an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with bioerodible Durasert E™. Supported by robust safety and efficacy data to date, DURAVYU is presently in Phase 3 global, pivotal clinical trials for wet age-related macular degeneration (wet AMD), the leading cause of vision loss among people 50 years of age and older in the United States, and in a Phase 2 clinical trial in diabetic macular edema (DME). Based on positive Phase 2 results from the VERONA clinical trial in DME, EyePoint anticipates initiation of a Phase 3 pivotal program by the end of 2025 with topline data from both Phase 3 pivotal trials in wet AMD in 2026.
Pipeline programs include EYP-2301, a TIE-2 agonist, razuprotafib, formulated in Durasert E™ to potentially improve outcomes in serious retinal diseases. The proven Durasert® drug delivery technology has been safely administered to thousands of patient eyes across four U.S. FDA approved products in multiple disease indications. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts.
Vorolanib is licensed to EyePoint exclusively by Equinox Sciences, a Betta Pharmaceuticals affiliate, for the localized treatment of all ophthalmic diseases outside of China, Macao, Hong Kong and Taiwan.
DURAVYU™ has been conditionally accepted by the FDA as the proprietary name for EYP-1901. DURAVYU is an investigational product; it has not been approved by the FDA. FDA approval and the timeline for potential approval is uncertain.
For EyePoint Pharmaceuticals:
Investors:
Christina Tartaglia
Precision AQ
Direct: 212-698-8700
christina.tartaglia@precisionaq.com
Media Contact:
Amy Phillips
Green Room Communications
Direct: 412-327-9499
aphillips@greenroompr.com
FAQ
How many shares were granted in EyePoint Pharmaceuticals (EYPT) February 2025 inducement awards?
What is the exercise price for EYPT's February 2025 inducement stock options?
What is the vesting schedule for EYPT's February 2025 inducement stock options?
How long is the term of EYPT's February 2025 inducement stock options?
